Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630377 | 1.00 | MMP9 (0.46) | MMP9MMP8TRPM8MMP1MAPT | |
| SCHEMBL1630380 | 1.00 | MMP9 (0.46) | MMP9MMP8TRPM8MMP1MAPT | |
| SCHEMBL19602425 | 0.81 | MMP9 (0.52) | MMP9MMP8TRPM8MMP1MAPT | |
| SCHEMBL24814077 | 0.79 | MMP9 (0.53) | MMP9MMP8TRPM8MMP1MAPT | |
| SCHEMBL30751663 | 0.79 | MMP9 (0.53) | MMP9MMP8TRPM8MMP1MAPT | |
| SCHEMBL9545042 | 0.79 | KLK5 (0.54) | MMP9MMP8TRPM8MAPTMEN1 | |
| SCHEMBL30751650 | 0.79 | KLK5 (0.54) | MMP9MMP8TRPM8MAPTMEN1 | |
| SCHEMBL24814238 | 0.79 | KLK5 (0.54) | MMP9MMP8TRPM8MAPTMEN1 | |
| SCHEMBL9545038 | 0.79 | KLK5 (0.54) | MMP9MMP8TRPM8MAPTMEN1 | |
| SCHEMBL1774282 | 0.78 | MMP9 (0.47) | MMP9MMP8TRPM8MMP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183260-B1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2183260-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009032180-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | POLI, ITPA, POLR2H | MMP9 2888/4885MMP8 1306/4885TRPM8 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.